We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Calcitonin Doubling Rate Sharpens Postoperative Recurrence Risk Stratification in Medullary Thyroid Carcinoma With Biochemical Persistent Disease

MedXY Editorial Team•May 4, 2026•Diabetes & Endocrinology
biochemical persistent diseasecalcitonin doubling ratemedullary thyroid carcinomaRecurrence Risk

Proposed article structure

This topic is best organized around the clinical problem of biochemical persistence after surgery for medullary thyroid carcinoma, the rationale for dynamic biomarker kinetics, the retrospective cohort design, the main prognostic findings, and the implications for surveillance and risk-adapted follow-up. A clinically useful structure is: Highlights; Background and unmet need; Study design and methods; Key results; Clinical interpretation and expert commentary; Practice implications; Limitations; Conclusion; Funding and trial registration; References.

Highlights

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Compartment-Specific Nodal Recurrence in Medullary Thyroid Cancer: Evaluating the Role of Contralateral Prophylactic Central Neck DissectionThis multicenter study assesses recurrence patterns in medullary thyroid cancer, finding ipsilateral neck sites are the most common recurrence locations, with limited evidence supporting routine contralateral prophylactic central neck disseSep 7, 2026Recurrent Severe Hypertensive Disorders in Pregnancy: Evaluating Risks and Outcomes for Future PregnanciesThis study delineates the significant recurrence risk of severe hypertensive disorders of pregnancy, especially early-onset cases, highlighting implications for patient counseling and management in subsequent pregnancies.Aug 21, 2026Combining Anatomical and Histologic Response Predicts Recurrence After Surgery for Colorectal Liver MetastasesA multi-institutional study of 483 patients shows that combining macroscopic (TBSr) and histologic (TRG) response to neoadjuvant therapy better stratifies recurrence risk after hepatectomy for colorectal liver metastases than either measure alone.Jul 29, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Recurrent Venous Thromboembolism After Isolated Distal DVT: Insights from the RIDTS Trial
This article reviews the incidence and predictors of recurrent VTE following anticoagulation for isolated distal deep vein thrombosis, highlighting key risk factors and implications for treatment duration and patient management.
Jul 7, 2026
Revisiting Level VII Lymph Node Metastasis in Medullary Thyroid Cancer: A Crucial Prognostic SubgroupLevel VII lymph node metastasis in medullary thyroid cancer signifies a highly aggressive phenotype with the poorest prognosis. Reclassifying level VII nodes as N1b improves prognostic accuracy and could refine staging and treatment strategJun 25, 2026
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on SelpercatinibThis case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.Jun 11, 2026